Advancing a platform of a novel drug class, redox-active metalloporphyrins, for the treatment of cancer patients.
BioMimetix, founded in 2013, is a pioneering small biotechnology firm at the forefront of transforming the landscape of cancer treatment with our novel compound, BMX-001. Leveraging groundbreaking research, we have developed a redox-active compound poised to revolutionize cancer treatment.
With a strategic focus on effective resource management, our company has demonstrated exceptional financial acumen over the past decade and completion of exciting Phase 2 data.
New drug class preparing for Phase 3 pivotal trial in high-grade glioma
Demonstrated clinical efficacy in multiple oncology indications
Platform drug transforming chemoradiation in multiple cancers
Unique dual action
enhances
tumor killing
and protects healthy tissue
